Tango Therapeutics Inc (TNGX) 13F Ownership Report (Q2 2026)

Tango Therapeutics (TNGX) filed an 8-K to update its at-the-market (ATM) equity program. The company had a sales agreement with Leerink Partners from November 2025 allowing up to $100 million in common stock sales, of which roughly $64.39 million had been sold, leaving about $35.61 million unsold. On August 11, 2026, it filed a new prospectus supplement that expands that capacity to up to $400 million and absorbs the remaining balance, terminating further sales under the old supplement. The filing covers capacity, not actual shares sold.

Tango Therapeutics (ticker: TNGX) put out a press release on August 11, 2026, covering its operating results and financial condition for the quarter ended June 30, 2026. The release is attached as Exhibit 99.1 to this Form 8-K. Importantly, the exhibit is being "furnished" rather than "filed," so it doesn't trigger Section 18 liability under the Securities Exchange Act and isn't automatically incorporated into other SEC filings. One honest caveat: the excerpt itself contains no actual financial figures—it only confirms that the earnings press release was issued.

Tango Therapeutics filed an 8-K disclosing that Dr. Weber signed a separation agreement on August 6, 2026. Under the terms, she receives salary continuation through December 31, 2026, COBRA premium reimbursement, accelerated vesting of outstanding options and restricted stock units (subject to Compensation Committee approval), an extended option exercise period, and a pro-rated share of any 2026 incentive bonus. The full agreement is attached as Exhibit 10.1.

AI summary pending